Remove Antibody Remove Bioassay Remove Bioinformatics Remove RNA
article thumbnail

Reflecting on PEGS Europe 2023 

Drug Discovery World

The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. It was presented by Xiaole Shirley Liu, PhD, CEO, GV20 Therapeutics, and titled: ‘AI-based target and antibody discovery from patient tumour profiles’.